Indian share markets settled at new closing highs for a third straight session today. At the closing bell, the BSE Sensex finished higher by 90 points. While, the NSE Nifty finished higher by 13 points. Meanwhile, the S&P BSE Midcap Index ended down by 0.4% while S&P BSE Small Cap Index ended up by 0.1% respectively.
Sectoral indices ended the day on a mixed note with realty stocks and consumer durables stocks leading the gainers. While, power stocks and healthcare stocks ended the day in red.
Overseas, Asian stock markets finished higher today with shares in Japan leading the region. The Nikkei 225 is up 0.57% while Hong Kong's Hang Seng is up 0.36% and China's Shanghai Composite is up 0.13%. European markets are higher today with shares in France leading the region. The CAC 40 is up 0.49% while London's FTSE 100 is up 0.31% and Germany's DAX is up 0.21%.
The rupee was trading at Rs 63.47 against the US$ in the afternoon session.
Coal India share price rallied over 5.6% in the opening trade on the reports that it has raised prices of thermal coal by an average 9%. The decision was taken at a board meeting held on Monday while revised prices would be effective from today. It will make power generation costlier by a similar percentage. Cost of cement and fertiliser production is also expected to rise as a result.
In another development, rating agency, CRISIL in its latest report has maintained its projection of India's economic growth in 2018-19 to 7.6% on the low base.
The rating agency attributed the continuing slowdown to the after-effects of the demonetisation exercise, the Goods and Services Tax (GST) implementation and weakness in agriculture.
The CRISIL note comes days after the Central Statistics Office (CSO) came out with its First Advance Estimates of National Income, 2017-18, in which it stated that Indian economy is expected to grow at a four-year low of 6.5% in the current fiscal year 2017-18, as against 7.1% in the fiscal year 2016-17.
The rating agency has stated that given the low base and the expected waning of the GST impacts going ahead, they retain their forecast of 7.6% real GDP growth in fiscal 2019, with private consumption leading the recovery.
It noted that private consumption is expected to grow 6.3% in FY18, as against 8.7% a year before, and will remain the largest contributor to the country's GDP at 55.7%.
Further, it said that in FY19 as well, growth will continue to be consumption-led as inflation will be under control and interest rates are expected to be soft. It also said that increase in government employees' salaries with the implementation of the seventh pay panel recommendations will also help. It added that the government's focus on spending towards agriculture and rural themes will also be of help.
According to the report, the government's ambitious Rs 2.11 trillion recapitalisation plan over two years will ensure that the state-run banks are well positioned to support the growth. It also observed that support to growth will also come from the external sector where the global recovery should help exports, which had faced some headwinds after the GST implementation.
In the news from the pharma sector. Orchid Pharma share price soared over 4.9% after it received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA).
Reportedly, USFDA successfully completed inspection for the Post-Marketing Adverse Drug Experience reporting inspection (PADE) conducted in Tamil Nadu, India.
The facility was inspected by USFDA in the month of June 2017.
One shall note that, as per the Indian Pharmaceutical Alliance, the pace of drug approvals has gained momentum after they complained to FDA about delays last year.
Approvals for drugs have also picked up after USFDA concerns at some of the manufacturing units were addressed. Companies such as Divi's Laboratories, Cadila Healthcare, Sun Pharmaceuticals and Dr Reddy's Laboratories got regulatory clearances for some of their plants during the year. But several companies are still grappling to resolve FDA concerns.
However, FDA's move to speed up generic drug approvals in a bid to reduce healthcare costs is likely to provide some earnings relief to domestic pharma companies.
After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.
Generic Drug Approvals Hit The Roof
With an aim to lower the overall healthcare costs in the country, USFDA approved a record 763 generic drugs for the financial year ending 30th September. As per Mint Analysis, Indian pharma companies received 295 approvals accounting for 40% of the overall approvals during the year.
Even the total filings of abbreviated new drug applications (ANDAs) for generic drugs rose to 1,292 in FY17 from 852 in FY16.
In such an environment, it makes sense for investors to be selective while buying stocks. Focus on value and the underlying fundamentals of the business. Then, they need not worry about the market.
So, what is key to identifying potential multibagger stocks? How does one pick them at the right time and ride them to their full potential? How many multibaggers do you really need to achieve the big riches that you desire?
Most importantly, are there any stocks right now that could turn out to be multibaggers? Click here to know everything that you need to know right now about mutlibagger stocks...
And here's a note from Profit Hunter:
Coal India is showing strong trading momentum. It rallied more than 15% for the past seven trading sessions to achieve a high of 311.
Last time, we mentioned that 240 is the strong support level for the stock. The level acted as support in August 2013 and February 2014. In August 2017, it bounced up from this level after forming an inverse head and shoulder patternto touch a high of 295 in October 2017.
It corrected from this high to find support from the inverse head-and-shoulder pattern's neckline. The stock also formed a double bottom pattern near the neckline. Recently, it broke out of this pattern (red line), and it also broke above the falling trendline (blue line) as seen in the chart below.
Today, the stock opened gap up and rallied nearly 6% with healthy volumes to cross above its previous high of 295.
So can the stock maintain its strong momentum in the sessions to come? Let's wait and watch.
Coal India Rallied 6% for the Day
This article was originally published in English at www.equitymaster.com
Read the complete Indian stock market update. For the terms of use, go here.
No comments:
Post a Comment